KCT0005164
Recruiting
N/A
A prospective study to evaluate the efficacy and safety of a new knife in endoscopic submucosal dissection for gastric neoplasm
ConditionsNeoplasms
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Neoplasms
- Sponsor
- Asan Medical Center
- Enrollment
- 100
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. 19 years old or older
- •2\. Diagnosed as adenoma or early gastric cancer and meets the indications for endoscopic resection
- •3\. Where he/she voluntarily signed a written informed consent form after hearing an explanation of the purpose, method, effect, etc. of the study
Exclusion Criteria
- •1\. Women of childbearing potential who are unable to use adequate contraception or are pregnant or lactating
- •2\. Past history of gastrectomy
- •3\. When endoscopic resection cannot be safely performed due to hemorrhagic disease or coagulation disorder
- •4\. When the investigator determines that endoscopic resection is impossible
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
N/A
A prospective study to evaluate the efficacy and safety of pregabalin for triweekly abraxane-induced peripheral neuralgiaBreast cancerJPRN-UMIN000006987Kinki University Faculty of Medicine30
Completed
Phase 2
Prospective study of evaluating the efficacy and safety of Radium-223 dichloride in patients with castration-resistant prostate cancer and bone metastasescastration-resistant prostate cancer with bone metastasesJPRN-UMIN000023897ational Hospital Organization Saitama Hospital20
Not Yet Recruiting
N/A
effect of alpha blockers in benign prostatic hyperplasiaHealth Condition 1: N401- Benign prostatic hyperplasia withlower urinary tract symptomsCTRI/2021/04/033122DR I C VIGNESH RAJA
Active, Not Recruiting
Phase 2
A prospective study of investigating the efficacy of FOLFIRI plus Aflibercept as a 2nd line therapy after progression during FOLFOXIRI plus Bevacizumab in unrescetable / metastatic colorectal cancer (CRC) patients.Colorectal CancerJPRN-jRCTs071190003Oki Eiji35
Recruiting
N/A
A prospective study to assess the efficacy and safety of the BlueWind RENOVA iStim* System for the treatment of patients diagnosed with overactive bladder (OASIS - OverActive bladder StImulation System study)Overactive bladderfrequent need to urinate10004994NL-OMON55598BlueWind Medical Ltd.25